Ngā hua rapu - Cheng‐Pang Hsu
- E whakaatu ana i te 1 - 4 hua o te 4
-
1
Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma mā Robert H.I. Andtbacka, Thomas Amatruda, John Nemunaitis, Jonathan S. Zager, John Walker, Jason Chesney, Kate Liu, Cheng‐Pang Hsu, Cheryl A. Pickett, Janice M. Mehnert
I whakaputaina 2019Artigo -
2
A First-in-Human Study of Conatumumab in Adult Patients with Advanced Solid Tumors mā Roy S. Herbst, Razelle Kurzrock, David S. Hong, Manuel Valdivieso, Cheng‐Pang Hsu, Lovely Goyal, Gloria Juan, Yuying C. Hwang, F. Susan Wong, John S. Hill, Greg Friberg, Patricia LoRusso
I whakaputaina 2010Artigo -
3
TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first‐line treatment of metastatic colorectal cancer mā Charles S. Fuchs, Marwan Fakih, Lee S. Schwartzberg, Allen Lee Cohn, Lorrin Yee, Luke Dreisbach, Mark Kozloff, Yong‐jiang Hei, Francesco Galimi, Yang Pan, Vincent Haddad, Cheng‐Pang Hsu, Antony Sabin, Leonard B. Saltz
I whakaputaina 2013Artigo -
4
A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer mā Luis Paz‐Ares, Beatrix Bálint, Richard H. De Boer, Jan P. van Meerbeeck, Rafal Wierzbicki, Paul de Souza, Francesco Galimi, Vincent Haddad, Tony Sabin, Yong-Jiang Hei, Yang Pan, Susan Cottrell, Cheng‐Pang Hsu, Rodryg Ramlau
I whakaputaina 2013Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Internal medicine
Medicine
Adverse effect
Chemotherapy
Gastroenterology
Pathology
Alternative medicine
Cancer
Lung cancer
Placebo
Tolerability
Anemia
Bevacizumab
Cancer research
Carboplatin
Cisplatin
Clinical endpoint
Cohort
Colorectal cancer
Confidence interval
Hazard ratio
Herpes simplex virus
Melanoma
Neutropenia
Oncology
Oncolytic virus
Oral mucosa
Paclitaxel
Performance status
Pharmacokinetics